Evidence map›Paper›PMID 29861844›Full record

ArticleOncotarget2018

Transcriptome analysis reveals a long non-coding RNA signature to improve biochemical recurrence prediction in prostate cancer.

Jinyuan Xu, Yujia Lan, Fulong Yu, Shiwei Zhu, Jianrong Ran, Jiali Zhu, Hongyi Zhang, Lili Li, Shujun Cheng, Yun Xiao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jinyuan Xu *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Yujia Lan *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Fulong Yu *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Shiwei Zhu *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Jianrong RanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Jiali ZhuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Hongyi ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Lili LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Shujun ChengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Yun XiaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Xia LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite highly successful treatments for localized prostate cancer (PCa), prognostic biomarkers are needed to improve patient management and prognosis. Accumulating evidence suggests that long noncoding RNAs (lncRNAs) are key regulators with biological and clinical significance. By transcriptome analysis, we identified a set of consistently dysregulated lncRNAs in PCa across different datasets and revealed an eight-lncRNA signature that significantly associated with the biochemical recurrence (BCR)-free survival. Based on the signature, patients could be classified into high- and low-risk groups with significantly different survival (HR = 2.19; 95% CI = 1.67-2.88;

Indexed as

BCR-free survivallncRNA signatureprognosisprostate cancertranscriptome

Identifiers

PMID29861844
PMCPMC5982764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.